Global Blood Therapeutics, Inc. (GBT) Financial Statements (2025 and earlier)

Company Profile

Business Address 181 OYSTER POINT BLVD
SOUTH SAN FRANCISCO, CA 94080
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

6/30/2022
MRQ
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including: 734,800494,766302,237275,357314,825147,274
Cash and cash equivalent 684,717494,766302,237275,357198,33292,072
Short-term investments     116,49355,202
Other undisclosed cash, cash equivalents, and short-term investments 50,083     
Receivables 28,80017,5002,637   
Inventory, net of allowances, customer advances and progress billings 58,20240,2231,277   
Inventory 58,20240,2231,277   
Prepaid expense  12,5999,4226,3373,8391,983
Other current assets    1,9095,648512
Other undisclosed current assets (19,832)67,075312,424202,177  
Total current assets: 801,970632,163627,997485,780324,312149,769
Noncurrent Assets
Operating lease, right-of-use asset 48,01550,72252,775
Property, plant and equipment 34,91837,88227,11314,98116,5712,420
Long-term investments and receivables 50,057   14,60750,058
Long-term investments 50,057   14,60750,058
Restricted cash and investments 2,4362,4362,3952,3951,046140
Other noncurrent assets 1,812799789206184 
Other undisclosed noncurrent assets   85,030114,281  
Total noncurrent assets: 137,23891,839168,102131,86332,40852,618
TOTAL ASSETS: 939,208724,002796,099617,643356,720202,387
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 82,10674,19669,55732,87425,89114,606
Employee-related liabilities 27,71223,98517,57810,0368,5794,967
Accounts payable 15,09719,07810,6216,0467,1774,320
Accrued liabilities 39,29731,13341,35816,79210,1355,319
Other liabilities 5,8924,8361,896899373909
Total current liabilities: 87,99879,03271,45333,77326,26415,515
Noncurrent Liabilities
Long-term debt and lease obligation 319,858227,991145,918   
Long-term debt, excluding current maturities 246,352148,81573,559   
Liabilities, other than long-term debt 8538223411,07111,652563
Other liabilities 8538223411,07111,652563
Operating lease, liability 73,50679,17672,359
Other undisclosed noncurrent liabilities 334,089     
Total noncurrent liabilities: 654,800228,813145,95211,07111,652563
Total liabilities: 742,798307,845217,40544,84437,91616,078
Equity
Equity, attributable to parent 196,410416,157578,694572,799318,804186,309
Common stock 656261564637
Additional paid in capital 1,485,8051,402,2621,316,7951,044,941617,051367,371
Accumulated other comprehensive income (loss) 100302754(48)(336)(166)
Accumulated deficit (1,289,560)(986,469)(738,916)(472,150)(297,957)(180,933)
Total equity: 196,410416,157578,694572,799318,804186,309
TOTAL LIABILITIES AND EQUITY: 939,208724,002796,099617,643356,720202,387

Income Statement (P&L) ($ in thousands)

6/30/2022
TTM
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Revenues 194,749123,8032,108   
Cost of revenue
(Cost of Product and Service Sold)
 (3,316)(1,986)    
Gross profit: 191,433121,8172,108   
Operating expenses (479,123)(365,973)(291,644)(182,742)(119,245)(83,127)
Other undisclosed operating income  9848,253   
Operating loss: (287,690)(243,172)(281,283)(182,742)(119,245)(83,127)
Nonoperating expense
(Other Nonoperating expense)
 (14,924)(4,381)    
Interest and debt expense (104,063)(48,938)(31,218)   
Loss from continuing operations before equity method investments, income taxes: (406,677)(296,491)(312,501)(182,742)(119,245)(83,127)
Other undisclosed income from continuing operations before income taxes 104,06348,93845,7398,5522,221659
Loss from continuing operations before income taxes: (302,614)(247,553)(266,762)(174,190)(117,024)(82,468)
Income tax expense (477)     
Loss from continuing operations: (303,091)(247,553)(266,762)(174,190)(117,024)(82,468)
Loss before gain (loss) on sale of properties:(303,091)(247,553)(266,762)(174,190)(117,024)(82,468)
Net loss: (303,091)(247,553)(266,762)(174,190)(117,024)(82,468)
Other undisclosed net loss attributable to parent   (4)(3)  
Net loss available to common stockholders, diluted: (303,091)(247,553)(266,766)(174,193)(117,024)(82,468)

Comprehensive Income ($ in thousands)

6/30/2022
TTM
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss: (303,091)(247,553)(266,762)(174,190)(117,024)(82,468)
Other comprehensive loss (202)     
Comprehensive loss: (303,293)(247,553)(266,762)(174,190)(117,024)(82,468)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent  (452)798285(170)(166)
Comprehensive loss, net of tax, attributable to parent: (303,293)(248,005)(265,964)(173,905)(117,194)(82,634)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: